We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$82.5B
AUM Growth
+$5.26B
(+6.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
962
New
129
Increased
342
Reduced
292
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$429M |
| 2 |
Airbnb
ABNB
|
+$235M |
| 3 |
T-Mobile US
TMUS
|
+$156M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$139M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deere & Co
DE
|
+$488M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$222M |
| 3 |
Expeditors International
EXPD
|
+$191M |
| 4 |
Qualcomm
QCOM
|
+$187M |
| 5 |
CERN
Cerner Corp
CERN
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.12% |
| 2 | Consumer Discretionary | 15.99% |
| 3 | Communication Services | 13.72% |
| 4 | Healthcare | 12.84% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CONMED
CNMD
$1.47B
| $93.2M | 0.11% |
678,058
+32,319
| +5% | +$4.42M |
|
77
Advanced Energy
AEIS
$13B
| $92.5M | 0.11% |
820,699
-167,455
| -17% | -$17.7M |
|
78
KBR
KBR
$4.8B
| $90.3M | 0.11% |
2,367,296
-4,503
| -0.2% | -$179K |
|
79
HDFC Bank
HDB
$121B
| $89.9M | 0.11% |
2,459,690
-22,904
| -0.9% | -$839K |
|
80
Vail Resorts
MTN
$5.3B
| $89.8M | 0.11% |
283,750
-6,495
| -2% | -$2.07M |
|
81
Halozyme
HALO
$12.2B
| $89.7M | 0.11% |
1,975,194
-6,062
| -0.3% | -$268K |
|
82
Texas Roadhouse
TXRH
$13.7B
| $89.1M | 0.11% |
926,115
+3,679
| +0.4% | +$362K |
|
83
Simply Good Foods
SMPL
$982M
| $86.1M | 0.1% |
2,357,372
+1,782
| +0.1% | +$60.9K |
|
|
AXNX
84
DELISTED
Axonics, Inc. Common Stock
AXNX
| $85.2M | 0.1% |
1,343,866
+325,275
| +32% | +$19.2M |
|
85
Hamilton Lane
HLNE
$5.57B
| $82.4M | 0.1% |
904,839
-1,886
| -0.2% | -$171K |
|
86
UFP Industries
UFPI
$5.19B
| $82.4M | 0.1% |
1,108,283
-18,168
| -2% | -$1.43M |
|
87
MACOM Technology Solutions
MTSI
$23.7B
| $75.4M | 0.09% |
1,176,503
-23,863
| -2% | -$1.38M |
|
88
BlackLine
BL
$1.72B
| $75.2M | 0.09% |
676,187
+3,777
| +0.6% | +$412K |
|
|
CTLT
89
DELISTED
CATALENT, INC.
CTLT
| $73.3M | 0.09% |
678,251
-6,423
| -0.9% | -$688K |
|
90
Rambus
RMBS
$11B
| $73.1M | 0.09% |
3,083,840
+505,189
| +20% | +$10.2M |
|
91
Columbia Sportswear
COLM
$2.94B
| $72.8M | 0.09% |
739,726
+86,570
| +13% | +$9.08M |
|
92
MSCI
MSCI
$40.9B
| $71.7M | 0.09% |
134,518
-16,529
| -11% | -$7.88M |
|
93
HealthEquity
HQY
$8.75B
| $71.6M | 0.09% |
890,188
+116,088
| +15% | +$8.84M |
|
94
AtriCure
ATRC
$2.11B
| $71.5M | 0.09% |
901,569
-18,299
| -2% | -$1.33M |
|
95
Kratos Defense & Security Solutions
KTOS
$11.4B
| $70.8M | 0.09% |
2,484,247
-50,578
| -2% | -$1.34M |
|
|
WNS
96
DELISTED
WNS Holdings
WNS
| $70.1M | 0.08% |
877,420
-17,800
| -2% | -$1.32M |
|
97
Novanta
NOVT
$6.29B
| $69.4M | 0.08% |
514,908
-10,347
| -2% | -$1.39M |
|
98
Frontdoor
FTDR
$6.26B
| $69.3M | 0.08% |
1,391,585
-22,084
| -2% | -$1.16M |
|
99
Pacira BioSciences
PCRX
$997M
| $68.3M | 0.08% |
1,126,199
-6,384
| -0.6% | -$404K |
|
100
Varonis Systems
VRNS
$5B
| $68.3M | 0.08% |
1,185,617
-23,756
| -2% | -$1.24M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2021 Portfolio in Review
As of Q2 2021, Loomis, Sayles & Company held 962 positions worth $82.5B, up 6.8% from $77.2B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Loomis, Sayles & Company's Q2 2021 filing shows 129 new, 342 increased, 292 reduced and 136 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 946,065 shares worth $160M. The largest sale was Deere & Co, an estimated $488M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q2 2021 buy was Alnylam Pharmaceuticals: 946,065 shares worth $160M.
- Loomis, Sayles & Company added most to Vertex Pharmaceuticals in Q2 2021, an estimated $429M increase.
- Loomis, Sayles & Company's biggest Q2 2021 reduction was Deere & Co, cutting an estimated $488M.
- Loomis, Sayles & Company fully exited Goosehead Insurance in Q2 2021, selling an estimated $66.6M.
- Loomis, Sayles & Company's ten largest holdings make up 39% of its $82.5B portfolio in Q2 2021.
- Loomis, Sayles & Company opened 129 new positions and closed 136 in Q2 2021.
- Loomis, Sayles & Company's portfolio value rose 6.8% quarter-over-quarter to $82.5B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.